MRVI · Maravai Lifesciences Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.84M | - | $41.63M | $47.40M | $46.85M | - | $65.20M | $73.40M | $64.18M | - |
| Cost of Revenue | $32.14M | - | $35.98M | $39.63M | $39.13M | - | $36.83M | $38.27M | $38.34M | - |
| Gross Profit | $33.70M | - | $32.23M | $7.77M | $7.72M | - | $28.37M | $35.13M | $25.84M | - |
| R&D | $3.89M | - | $3.84M | $4.88M | $4.89M | - | $4.34M | $5.28M | $5.03M | - |
| SG&A | $29.09M | - | $35.40M | $38.58M | $39.56M | - | $39.09M | $40.56M | $40.88M | - |
| Total Operating Expenses | $35.86M | - | $46.69M | $113.67M | $96.01M | - | $234.31M | $82.91M | $83.04M | - |
| D&A | $4.90M | - | $5.97M | $5.96M | $5.69M | - | $5.04M | $5.56M | $4.79M | - |
| Operating Income | ($2.16M) | - | ($41.03M) | ($66.28M) | ($49.16M) | - | ($169.11M) | ($9.51M) | ($18.86M) | - |
| Interest Expense | $5.75M | - | $6.84M | $6.82M | $10.86M | - | $13.63M | $11.94M | $10.86M | - |
| Income Tax | ($151.0K) | - | ($92.0K) | ($4.29M) | $162.0K | - | $311.0K | ($2.44M) | $271.0K | - |
| Net Income | ($3.73M) | - | ($25.56M) | ($39.59M) | ($29.95M) | - | ($99.04M) | ($7.58M) | ($12.08M) | - |
| EPS - Basic | ($0.02) | - | ($0.18) | ($0.27) | ($0.21) | - | ($0.70) | ($0.05) | ($0.09) | - |
| EPS - Diluted | ($0.02) | - | ($0.18) | ($0.27) | ($0.21) | - | ($0.70) | ($0.05) | ($0.09) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $165.92M | $216.89M | $243.57M | $269.91M | $285.05M | $322.40M | $578.16M | $573.17M | $561.69M | $574.96M |
| Accounts Receivable | $33.41M | $25.50M | $22.54M | $27.88M | $28.49M | $38.52M | $28.87M | $38.65M | $36.69M | $54.60M |
| Inventory | $40.46M | $40.49M | $45.33M | $46.67M | $49.77M | $50.08M | $50.41M | $49.29M | $49.85M | $51.40M |
| Accounts Payable | $8.54M | $2.91M | $8.00M | $11.53M | $9.53M | - | - | - | - | - |
| Current Assets | $251.74M | $296.25M | $325.87M | $359.76M | $376.28M | $429.15M | $679.10M | $685.36M | $667.88M | $699.91M |
| Total Assets | $713.22M | $770.58M | $849.19M | $896.97M | $959.75M | $1.01B | $1.28B | $1.45B | $1.44B | $1.49B |
| Current Liabilities | $42.62M | $44.92M | $61.57M | $69.68M | $63.16M | $56.97M | $63.24M | $68.55M | $59.02M | $87.47M |
| Long-term Debt | $235.57M | $286.33M | $287.38M | $288.44M | $289.50M | $290.49M | $516.28M | $517.08M | $517.89M | $518.71M |
| Total Liabilities | $344.13M | $397.87M | $417.33M | $428.98M | $429.48M | $431.04M | $665.09M | $671.19M | $667.25M | $697.57M |
| Stockholders' Equity | $211.56M | $212.38M | $245.44M | $265.86M | $300.61M | $325.29M | $345.14M | $436.93M | $410.66M | $416.75M |
| Retained Earnings | $6.38M | $10.12M | $45.80M | $71.36M | $110.95M | $140.89M | $167.04M | $266.07M | $273.66M | $285.74M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $8.66M | - | - | - | ($9.39M) | - | - | - | ($8.47M) | - |
| Investing Cash Flow | ($4.44M) | - | - | - | ($23.13M) | - | - | - | ($4.24M) | - |
| Financing Cash Flow | ($55.23M) | - | - | - | ($4.90M) | - | - | - | ($560.0K) | - |
| CapEx | $4.44M | - | - | - | $5.24M | - | - | - | $5.67M | - |
| Free Cash Flow | $4.23M | - | - | - | ($14.63M) | - | - | - | ($14.13M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 51.2% | - | 77.4% | 16.4% | 16.5% | - | 43.5% | 47.9% | 40.3% | - |
| Operating margin | -3.3% | - | -98.6% | -139.8% | -104.9% | - | -259.4% | -13.0% | -29.4% | - |
| EBITDA margin | 4.2% | - | -84.2% | -127.3% | -92.8% | - | -251.6% | -5.4% | -21.9% | - |
| Net margin | -5.7% | - | -61.4% | -83.5% | -63.9% | - | -151.9% | -10.3% | -18.8% | - |
| Free cash flow margin | 6.4% | - | - | - | -31.2% | - | - | - | -22.0% | - |
| FCF / Net income | -1.13 | - | - | - | 0.49 | - | - | - | 1.17 | - |
| R&D / Revenue | 5.9% | - | 9.2% | 10.3% | 10.4% | - | 6.7% | 7.2% | 7.8% | - |
| SG&A / Revenue | 44.2% | - | 85.0% | 81.4% | 84.4% | - | 59.9% | 55.3% | 63.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.5% | - | -3.0% | -4.4% | -3.1% | - | -7.7% | -0.5% | -0.8% | - |
| Return on equity | -1.8% | - | -10.4% | -14.9% | -10.0% | - | -28.7% | -1.7% | -2.9% | - |
| Return on invested capital | -0.4% | - | -6.1% | -9.4% | -6.6% | - | -15.5% | -0.8% | -1.6% | - |
| Liquidity | ||||||||||
| Current ratio | 5.91 | 6.60 | 5.29 | 5.16 | 5.96 | 7.53 | 10.74 | 10.00 | 11.32 | 8.00 |
| Quick ratio | 4.96 | 5.69 | 4.56 | 4.49 | 5.17 | 6.65 | 9.94 | 9.28 | 10.47 | 7.41 |
| Cash ratio | 3.89 | 4.83 | 3.96 | 3.87 | 4.51 | 5.66 | 9.14 | 8.36 | 9.52 | 6.57 |
| Leverage | ||||||||||
| Debt / Equity | 1.11 | 1.35 | 1.17 | 1.08 | 0.96 | 0.89 | 1.50 | 1.18 | 1.26 | 1.24 |
| Debt / Assets | 0.33 | 0.37 | 0.34 | 0.32 | 0.30 | 0.29 | 0.40 | 0.36 | 0.36 | 0.35 |
| Debt / EBITDA | 85.91 | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.4x | - | -6.0x | -9.7x | -4.5x | - | -12.4x | -0.8x | -1.7x | - |
| Equity multiplier | 3.37 | 3.63 | 3.46 | 3.37 | 3.19 | 3.10 | 3.70 | 3.31 | 3.52 | 3.57 |
| Liabilities / Assets | 0.48 | 0.52 | 0.49 | 0.48 | 0.45 | 0.43 | 0.52 | 0.46 | 0.46 | 0.47 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.05 | 0.05 | 0.05 | - | 0.05 | 0.05 | 0.04 | - |
| Inventory turnover | 0.79 | - | 0.79 | 0.85 | 0.79 | - | 0.73 | 0.78 | 0.77 | - |
| Days sales outstanding | 185d | - | 198d | 215d | 222d | - | 162d | 192d | 209d | - |
| Days inventory outstanding | 460d | - | 460d | 430d | 464d | - | 500d | 470d | 475d | - |
| Days payable outstanding | 97d | - | 81d | 106d | 89d | - | - | - | - | - |
| Cash conversion cycle | 548d | - | 576d | 538d | 597d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.0x | - | 1.7x | 1.3x | 1.1x | - | 3.4x | 2.2x | 2.8x | - |
| P / S | 6.3x | - | 10.0x | 7.3x | 6.8x | - | 18.0x | 13.3x | 17.9x | - |
| EV / EBITDA | 176.5x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 40.5% | - | -36.2% | -35.4% | -27.0% | - | -2.5% | 6.5% | -18.8% | - |
| Revenue CAGR (3y) | -5.9% | - | -39.8% | -42.0% | -42.3% | - | -9.5% | 16.1% | 8.0% | - |
| Revenue CAGR (5y) | 5.2% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 336.3% | - | 13.6% | -77.9% | -70.1% | - | -6.0% | 37.0% | -43.0% | - |
| Operating income growth (YoY) | 95.6% | - | 75.7% | -596.8% | -160.7% | - | -996.9% | 18.1% | - | - |
| Net income growth (YoY) | 87.5% | - | 74.2% | -422.0% | -147.9% | - | -1432.6% | -16.0% | -17926.9% | - |
| EPS growth (YoY) | 90.5% | - | 74.3% | -440.0% | -133.3% | - | -1300.0% | 0.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -3.5% | - | - | - | - | - |
| FCF CAGR (5y) | -7.7% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -29.6% | -34.7% | -28.9% | -39.2% | -26.8% | -21.9% | -33.5% | -16.1% | -21.3% | -23.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$185.74M totalTri Link Segment$119.79M · 64.5%
Cygnus Segment$65.96M · 35.5%
Geographic
$230.69M totalUS$110.90M · 48.1%
North America$85.22M · 36.9%
Asia Pacific$19.49M · 8.4%
EMEA$14.80M · 6.4%
Latin And Central America$278.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MARAVAI LIFESCIENCES HOLDINGS against the 5 most active filers in the same SIC group.